Form 4: BeOne Medicines Executive Executes Stock Sale
Statement of Changes in Beneficial Ownership
SVP and General Counsel Henry Lee Chan exercised stock options and sold American Depositary Shares under a 10b5-1 plan.
Summary
- Henry Lee Chan, SVP and General Counsel of BeOne Medicines, exercised options to acquire 332 American Depositary Shares (ADS) on May 13, 2026.
- The acquired shares were sold on the same day at a price of $310.72 per share.
- The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
- Following the transactions, the reporting person holds 318,370 ordinary shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction was conducted under a pre-arranged 10b5-1 plan, which is a standard administrative procedure for corporate insiders.
Positives
- The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.
Negatives
- The executive reduced their direct holdings of American Depositary Shares to zero through this specific transaction.
Risks
- Future share price volatility may impact the value of remaining unvested options held by the executive.
Future Outlook
No specific forward-looking guidance regarding company performance was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling under pre-established 10b5-1 plans is a standard corporate governance practice and typically does not signal a change in management's outlook on the company's long-term prospects.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for executives to manage equity holdings while avoiding potential insider trading allegations.
Stakeholder Impact
- Minimal impact expected as the transaction was pre-planned and represents a small portion of the executive's total holdings.
Next Steps
- Continued monitoring of future Form 4 filings for further insider activity.
Key Dates
| Date | Description |
|---|---|
| 05/14/2025 | Date the Rule 10b5-1 trading plan was adopted. |
| 05/13/2026 | Date of the reported option exercises and share sales. |
| 05/15/2026 | Date the Form 4 was filed with the SEC. |
Keywords
BeOne Medicines, ONC, Insider Trading, Form 4, Stock Options, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.